<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03627611</url>
  </required_header>
  <id_info>
    <org_study_id>2017/1883 (REK)</org_study_id>
    <secondary_id>2017-003673-34</secondary_id>
    <nct_id>NCT03627611</nct_id>
  </id_info>
  <brief_title>Identification of Non-responders to Levothyroxine Therapy</brief_title>
  <official_title>A Randomized Crossover Study, Examining Differential Effects of Levothyroxine and Liothyronine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hormonlaboratoriet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spesialistsenteret Pilestredet Park</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess differential effects of T4 and T3 on cell and tissue&#xD;
      level&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      15-20% of the patients with hypothyroidism remain symptomatic, despite adequate thyroxine&#xD;
      substitution. Endocrinologists are split in their opinion on combination therapy with T4 and&#xD;
      T3 on patients with poorly regulated hypothyroidism. There are no objective means, by which&#xD;
      to identify individuals who would benefit from combination therapy. The purpose of this study&#xD;
      is to assess differential effects of T4 and T3 on body temperature, metabolism, muscle&#xD;
      strength and brain function. The main aim is to try to identify biomarkers reflecting&#xD;
      different effects of T4 and T3 on cell and tissue level.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 14, 2018</start_date>
  <completion_date type="Actual">June 22, 2020</completion_date>
  <primary_completion_date type="Actual">June 22, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brown adipose tissue activation</measure>
    <time_frame>6 months</time_frame>
    <description>Thermal imaging of supraclavicular fossa</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body temperature</measure>
    <time_frame>6 months</time_frame>
    <description>Rectal thermometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Energy expenditure</measure>
    <time_frame>6 months</time_frame>
    <description>Indirect calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength</measure>
    <time_frame>6 months</time_frame>
    <description>Hand grip test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ThyPRO Questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>Thyroid patient reported outcome, 13 multi-item scale, range 0-100 with higher scores indicating poorer health status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean levels of thyroid hormones</measure>
    <time_frame>6 months</time_frame>
    <description>TSH, free T4 and free T3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 Questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>Short form health survey, 8 multi-item scale, range 0-100 with higher scores indicating better health status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>11 item, range 0-33 with higher scores implying higher levels of fatigue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New biomarkers</measure>
    <time_frame>6 months</time_frame>
    <description>Bone marrow fat, serum and urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Micro-RNA, miR-92a</measure>
    <time_frame>6 months</time_frame>
    <description>Serum exosomes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Hypothyroidism</condition>
  <condition>Biomarkers</condition>
  <condition>Endocrine System Diseases</condition>
  <arm_group>
    <arm_group_label>T4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>T3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levothyroxin</intervention_name>
    <description>3 months</description>
    <arm_group_label>T4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liothyronine</intervention_name>
    <description>3 months</description>
    <arm_group_label>T3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Poorly regulated hypothyroidism&#xD;
&#xD;
          -  Female aged between 18 and 65 years&#xD;
&#xD;
          -  Written informed consent obtained from the patient according to national regulations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiovascular disease&#xD;
&#xD;
          -  Chronic liver disease&#xD;
&#xD;
          -  Chronic kidney disease&#xD;
&#xD;
          -  Any other endocrinological disease&#xD;
&#xD;
          -  Use of beta blockers&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Hormonal substitution other than T3 and T4&#xD;
&#xD;
          -  Known psychiatric disease&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik Fink Eriksen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Endocrinology, Morbid Obesity and Preventive Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 25, 2018</study_first_submitted>
  <study_first_submitted_qc>August 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2018</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Erik Fink Eriksen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Thyroxine</keyword>
  <keyword>Triiodothyronine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypothyroidism</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

